IMV Inc. changes its Board of Directors

IMV Inc., a clinical-stage company developing a portfolio of immune-educating therapies, based on its novel DPX platform, to treat solid and hematologic cancers, yesterday announced changes to its board of directors as Shermaine Tilley, Ph.D., MBA has resigned from the Board of Directors (“Board”) of the Company, effective immediately. Dr. Tilley, Managing Partner at CTI […]